The largest pharmaceutical company in Japan, Takeda, is to invest €40m in a new facility at their Grange Castle site in Clondalkin, Dublin 22.
Takeda focuses its research and development efforts on oncology, gastroenterology and central nervous system therapeutic areas along with vaccines.
The investment by Takeda will bring the construction of a new standalone high containment production facility dedicated to manufacturing its oncology product NINLARO for global markets.
NINLARO was approved by the U.S. Food and Drug Administration in November 2015. In the U.S., NINLARO is used in the treatment of patients with myeloma cancer.
Takeda first set up operations in Ireland in 1997. In 2002, it chose Dublin as the location for its first active pharmaceutical ingredient facility outside of Japan.
Takeda currently employ 400 people at three sites in the Dublin area, this new investment will create approximately 40 new jobs.
Mr. Paul Keogh, Plant Director at Takeda Ireland Grange Castle said that the additional investment in Ireland demonstrates the confidence and commitment Takeda has in its Irish operation;
“We are delighted that Takeda has chosen Ireland for this investment and proud that we have been entrusted with the responsibility to produce and deliver this very important treatment for cancer patients worldwide. We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high quality products from our site”.
Welcoming the new investment by Takeda, Minister Mitchell O’Connor said;
“The pharma industry makes a huge contribution to the Irish economy in terms of jobs and exports, and is one of the fastest growing sectors. Takeda’s decision to manufacture their new cancer treatment in Ireland is a great win and vote of confidence in Ireland and it builds on our ongoing expansion of the sector here. I’m delighted that this investment will bring a further 40 jobs to the company’s existing Clondalkin facility”.
This investment is supported by IDA Ireland.